
Ep192: Kate Haviland on Following the Science to Precision Immunology
08/1/2026 | 1h 26 mins.
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
15/12/2025 | 1h 7 mins.
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Ep190: Neil Kumar on Building a Rare Disease Drug Company
20/11/2025 | 1h 13 mins.
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
12/11/2025 | 1h 12 mins.
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.

Ep188: Art Krieg on Innate Immune System Activators for Cancer
28/10/2025 | 1h 9 mins.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.



The Long Run with Luke Timmerman